Drugs / bexicaserin
bexicaserin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05364021 | Mar 2022 → Nov 2023 | Dravet syndrome, Lennox-Gastaut syndrome | Longboard Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05626634 | Nov 2022 → Dec 2024 | Dravet syndrome, Lennox-Gastaut syndrome | Longboard Pharmaceuticals | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06908226 | Feb 2025 → Nov 2027 expected | developmental and epileptic encephalopathy | Longboard Pharmaceuticals | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06719141 | Nov 2024 → Oct 2026 expected | developmental and epileptic encephalopathy | Longboard Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06660394 | Sep 2024 → Aug 2026 overdue | Dravet syndrome | Longboard Pharmaceuticals | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06149663 | — | Dravet syndrome, Lennox-Gastaut syndrome | Longboard Pharmaceuticals | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-12-06 | H. Lundbeck A/S | Results Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting lundbeck.com ↗ |
| 2025-12-02 | H. Lundbeck A/S | Results Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting lundbeck.com ↗
The comprehensive dataset includes a recent post-hoc analysis from Phase 1b/2a PACIFIC trial and Open-Label Extension (OLE) indicating patients with DEEs experienced an early response to bexicaserin which was sustained over the long-term. |
| 2025-08-25 | H. Lundbeck A/S | Results Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy lundbeck.com ↗
The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1 |
| 2025-04-04 | H. Lundbeck A/S | Results Lundbeck to present positive pipeline data at American Academy of Neurology (AAN) Annual Meeting lundbeck.com ↗
H. Lundbeck A/S (Lundbeck) will present positive interim results from the open-label extension of the PACIFIC trial investigating bexicaserin, in addition to new analyses from clinical trials and real-world data with eptinezumab. |
| 2025-01-30 | H. Lundbeck A/S | Results Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies lundbeck.com ↗
Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period. |
All press releases naming this drug 6 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bexicaserin | “LP352, bexicaserin” NCT05626634 ↗ |
| Known as | Bexicaserina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314507 ↗ |
| Known as | Bexicaserine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314507 ↗ |
| Known as | LP352 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05364021 ↗ |
| Modality | Small molecule | — CHEMBL5314507 ↗ |
| Route | Oral | “orally” NCT05364021 ↗ |